ArticleCytoJournal2026
Comparison of clinical and histopathological features between serum IgG4-negative and serum IgG4-positive patients with type 1 autoimmune pancreatitis: A single-center, retrospective study.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In type 1 autoimmune pancreatitis (AIP), serum immunoglobulin G4 (IgG4) has a complex correlation with pathology. In this study, clinical/histopathological traits of serum IgG4-negative/positive (N/P) patients were compared, and serum IgG4-tissue IgG4 correlations were explored to aid accurate diagnosis/typing. Material and Methods: A retrospective analysis was performed on 78 type 1 AIP patients (screened from 160 eligible cases through inclusion/exclusion criteria, International Consensus Diagnostic Criteria-confirmed at Changhai Hospital (December 2019-2023). At diagnosis, patients with serum IgG4 <135 mg/dL (n = 19) were assigned to the serum IgG4-N group, and those with serum IgG4 ≥135 mg/dL (n = 59) were assigned to the serum IgG4-P group. Clinical baseline data, laboratory indicators, imaging features (computed tomography/magnetic resonance imaging/endoscopic ultrasound guided [EUS]), and histopathological findings (from EUS fine-needle aspiration/fine-needle biopsy [EUS-FNA/FNB] or surgery) were compared. Statistical analysis (R 4.4.0) was conducted with Chi-square/Fisher's exact tests (categorical data) and Mann‒Whitney U tests (continuous data); Spearman correlation was used to assess serum IgG4-tissue IgG4 links. A Bonferroni-corrected Results: No significant differences in sex, age, most comorbidities (e.g., hypertension), or symptoms (e.g., abdominal discomfort) were observed between the serum IgG4-N and serum IgG4-P groups (all Conclusion: Serum IgG4 typing is associated with the clinical-pathological features of type 1 AIP. The serum IgG4-P group often shows biliary duct stenosis and diffuse pancreatic enlargement, with a reliance on EUS puncture. The serum IgG4-N group has higher CA19-9 and a higher surgical rate. Pathological examination remains critical (no serum-tissue IgG4 association). This study supports optimized, accurate diagnosis and stratified management of type 1 AIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.